ClinicalTrials.gg

Program

OJR520

A development code.

Its studies are mostly in Renal Insufficiency, Chronic, led by Novartis.

Furthest: phase 1, since Nov 14, 20251 company-led study, 1 open or runningNext primary completion: Jan 21, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 1since Nov 14, 2025Nov 14, 2025Jan 21, 2028phase 1 · NCT07235059
  • Named in Novartis’s own pipeline as OJR520, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT07235059 · 112 planned · United States, Germany

Ahead

  1. Jan 21, 2028Primary completion: phase 1 study in Renal Insufficiency, ChronicNCT07235059

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07235059Renal Insufficiency, Chronic · United States, Germany1RecruitingJan 21, 2028112

How it is read

Names in the registry

  • “OJR520”, 1 entry

Codes read as this program: OJR520.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.